Zoetis Executives Face Personal Liability in Securities Class Action

The litigation covers the period from January 14, 2025, to May 6, 2026. According to the complaint filed by Levi & Korsinsky, LLP, the defendants allegedly maintained false narratives regarding the growth of flagship products even as the firm faced mounting pressure from Elanco’s competing therapies and safety-related warnings concerning the drug Librela. Following a series of disclosures, Zoetis shares dropped 21.5% on May 7, 2026, closing at $87.31.

Legal arguments center on Section 20(a) of the Securities Exchange Act, which allows for individual liability for those in control of a company’s public statements. The suit argues that Peck and Joseph violated their Sarbanes-Oxley certification obligations by attesting to the accuracy of SEC filings while purportedly ignoring internal data on veterinarian prescription trends and declining market share. Investors seeking to serve as lead plaintiff in the action must file their applications with the court by July 27, 2026.